8-K: Iridex Reports Strong Q4, Full Year 2025 Financial Results

Iridex Corporation announced strong fourth quarter and full year 2025 financial results, driven by revenue growth and significant operating expense reductions.

Summary

• Total revenue for Q4 2025 was $14.7 million, representing 16% year-over-year growth.
• Total revenue for the full year 2025 was $52.7 million, an 8% increase compared to 2024.
• Achieved positive adjusted EBITDA of $1.1 million for the full year 2025, a first in recent company history.
• Operating expenses were reduced by 10% in Q4 2025 and 22% for the full year 2025.
• Net loss improved to $0.2 million ($0.01 per share) in Q4 2025, compared to $0.8 million ($0.05 per share) in Q4 2024.
• Full year 2025 net loss improved to $4.4 million ($0.26 per share), compared to $8.9 million ($0.54 per share) in 2024.
• Cash and cash equivalents stood at $6.0 million as of January 3, 2026, an increase of $0.4 million in the quarter.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive report, highlighting significant operational improvements, revenue growth, and the achievement of positive adjusted EBITDA, despite some gross margin pressure and geopolitical risks.

Positives

• Strong Q4 2025 revenue growth of 16% year-over-year to $14.7 million, driven by higher retina system sales, glaucoma probe sales, and an extra selling week.
• Full year 2025 revenue grew 8% to $52.7 million, primarily from higher retina system sales and glaucoma probe utilization.
• Achieved positive adjusted EBITDA of $1.1 million for the full year 2025, a significant improvement from a $4.3 million loss in 2024 and the first time in recent company history.
• Operating expenses were significantly reduced by 10% in Q4 2025 and 22% for the full year 2025 due to expense reduction measures.
• Net loss improved substantially in both Q4 2025 (to $0.2 million) and full year 2025 (to $4.4 million).
• Cash and cash equivalents increased by $0.4 million in Q4 2025, reaching $6.0 million.
• The company expects to generate positive operating cash flow in full year 2026.

Negatives

• Gross margin decreased to 37% in Q4 2025 from 44% in Q4 2024, primarily due to increased manufacturing costs, tariff developments, and lower capitalization of manufacturing overhead.
• Full year 2025 gross margin decreased to 37% from 40% in 2024, impacted by inventory write-downs, increased manufacturing costs, and tariffs.
• Sold fewer Cyclo G6 Glaucoma Laser Systems in Q4 2025 (44 units) compared to Q4 2024 (47 units).

Risks

• Market disruptions from the conflict in the Middle East are impacting product delivery timelines, leading to no contemplated 2026 sales in that region.
• Increased product costs associated with tariff developments throughout the year negatively impacted gross margins.
• The company cannot provide assurance that it will achieve or sustain profitability.
• Other risks are described in the Risk Factors section of Iridex's most recent Annual Report on Form 10-K.

Future Outlook

The company forecasts 2026 revenue to be between $51 million and $53 million. This guidance accounts for market disruptions from the Middle East conflict, contemplating no 2026 sales in that region. On a pro forma basis, excluding 2025 Middle East revenue, this represents 1% to 5% growth compared to 2025. Adjusted operating expenses for 2026 are expected to be in the range of $19 million to $19.5 million, and the company anticipates generating positive operating cash flow for the full year 2026.

Management Comments

• "2025 was a transformational year for Iridex, we grew revenue, reduced operating expenses, and achieved positive adjusted EBITDA for the first time in recent company history."
• "I am proud to announce that our fourth quarter was our strongest of the year, with momentum across both our glaucoma and retina businesses driving cash flow positive operations."
• "As we enter 2026, we have a growing installed base of systems, manufacturing efficiency initiatives underway and leaner cost structure, that position us to build on our 2025 progress and drive sustainable profitability."

Industry Context

StockSavvy.ai notes that Iridex's focus on laser-based medical systems for glaucoma and retinal diseases places it in a growing ophthalmology market, driven by an aging global population and increasing prevalence of eye conditions. The company's efforts to achieve positive adjusted EBITDA and reduce operating expenses align with broader industry trends towards efficiency and profitability, especially for smaller medical device companies. The impact of geopolitical conflicts on supply chains and market access, as seen with the Middle East, is a common challenge for global medical device manufacturers.

Comparison to Industry Standards

• StockSavvy.ai observes that Iridex's 8% full-year revenue growth to $52.7 million is competitive within the specialized ophthalmology device market, though larger players like Alcon (FY23 revenue $9.4 billion, 8% YOY growth) or Bausch + Lomb (FY23 revenue $4.1 billion, 8% YOY growth) operate on a much larger scale.
• The achievement of positive adjusted EBITDA for the first time in recent history is a significant milestone, indicating improved operational efficiency, which is crucial for smaller medical technology firms often focused on R&D and market penetration.
• The decline in gross margin from 40% to 37% year-over-year, attributed to manufacturing costs and tariffs, suggests challenges in cost management or pricing power compared to industry leaders who often maintain gross margins above 60-70% (e.g., Intuitive Surgical's Q4 2023 gross margin was 67.1%).
• The reduction in operating expenses by 22% for the full year demonstrates strong cost control, a positive sign for profitability, especially when compared to peers that might be increasing R&D or sales & marketing spend for aggressive market expansion.

Stakeholder Impact

• Shareholders: Potential positive impact due to improved financial performance, revenue growth, and a stated path towards sustainable profitability and positive operating cash flow.
• Employees: Impacted by expense reduction measures taken in late 2024, which led to reduced operating expenses.
• Customers: Continued availability of innovative laser-based medical systems for glaucoma and retinal diseases.
• Suppliers: Potential impact from tariff developments and increased manufacturing costs.

Next Steps

• Host a conference call on March 26, 2026, at 2:00 p.m. PT / 5:00 p.m. ET to discuss results.
• Continue manufacturing efficiency initiatives underway.
• Build on 2025 progress to drive sustainable profitability in 2026.
• Generate positive operating cash flow in full year 2026.

Key Dates

Recommendation

The company demonstrated strong operational improvements, achieving positive adjusted EBITDA and significant revenue growth. However, gross margin compression and geopolitical risks in the Middle East temper the overall outlook. While the trajectory is positive, the company is still navigating profitability challenges and external market disruptions, suggesting a "hold" until sustained profitability and margin improvement are clearly demonstrated.

Keywords

Iridex, IRIX, financial results, Q4 2025, full year 2025, glaucoma, retina, medical systems, laser, MicroPulse, adjusted EBITDA, revenue, operating expenses, financial outlook